Key result
Vitamin K antagonist use was associated with more hematomas compared to no antithrombotics (23% vs 11%, P=0.001), longer time to surgery, and longer admission duration.
Why the study?
Geriatric hip fracture patients frequently use antithrombotics due to cardiovascular comorbidities, but their effect on perioperative care and patient outcomes after hip hemiarthroplasty under current guidelines needed assessment.
Do antithrombotics (VKA or antiplatelet therapy) increase perioperative complications or mortality in patients undergoing hip hemiarthroplasty for femoral neck fracture?
Cohort (n=907)
Yes
Do antithrombotics (VKA or antiplatelet therapy) increase perioperative complications or mortality in patients undergoing hip hemiarthroplasty for femoral neck fracture?
Absolute Event Rate: 23% vs 11%
p-value: p=.001
In patients undergoing hip hemiarthroplasty, VKA and antiplatelet therapy increase bleeding-related complications and delay surgery, but do not negatively impact 30-day or 1-year mortality.
VKA use may increase bleeding and delays in hemiarthroplasty; leaves open optimal antithrombotic strategies and mortality effects.
Introduction Geriatric hip fracture patients are characterized by frailty due to multiple comorbidities, such as cardiovascular disease, in which the use of antithrombotics is frequent. The aim of this study is to assess the effect of antithrombotics on perioperative care and patient outcomes after hip hemiarthroplasty following current guidelines. Materials and Methods This observational cohort study included all consecutively admitted patients with a femoral neck fracture requiring hip hemiarthroplasty between January 1 st 2010, and May 16 th 2016, in two level II trauma teaching hospitals. Patients with multiple trauma injuries were excluded. Results In total, n = 907 patients (68% female (n = 615), median age 84 years) were included of which n = 142 used a vitamin K antagonist (VKA) and n = 213 used antiplatelet (AP) therapy. Both were associated with more packed cell supplementation (.4 ± 1.1 units and .3 ± .8 units vs .2 ± .6 units, P < .001 and P = .03, respectively). VKA was associated with more hematomas compared no antithrombotics (23% vs 11%, P = .001). VKA had a longer time to surgery compared to no antithrombotics and AP (24 hours vs 19 and 20 hours, P < .001 and P < .001, respectively) and longer admission duration (9 days vs 7 days P < .001. There were no differences in 30 day mortality nor in 1-year mortality rates. Discussion All modifiable causes for deep SSI, such as hematomas, should be prevented in acute hip fracture surgery. Since antithrombotics are associated with hematomas, an optimal handling in perioperative setting is necessary. Conclusion VKA was associated with longer time to surgery, more hematomas, and longer admission duration. VKA and AP were associated with more packed cell supplementation.
No takes yet. Share an insight, caveat, or question.
Rijckevorsel et al. (2021) conducted a cohort in femoral neck fracture (n=907). Antithrombotics (vitamin K antagonists or antiplatelet therapy) vs. No antithrombotics was evaluated on hematomas (p=.001). Vitamin K antagonist use was associated with more hematomas compared to no antithrombotics (23% vs 11%, P=0.001), longer time to surgery, and longer admission duration.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: